Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease

International Journal of Gynecological Cancer

Volumn 6, Issue 5, 1996, Pages 410-414

  Strauss, G ^a   Lund, B ^a   Hansen, M ^b   Hansen, O P ^c   Hansen, H H ^a  

^a Rigshospitalet   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

etoposide; high dose platinum; ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PLATINUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0029767668     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06050410.x     Document Type: Article

References (14)

1. Neijt JP, Ten Bokkel Huinik WW, Van der Burg MEL, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984; ii: 594-600.
2. Wiltshaw E. Ovarian trails at the Royal Marsden. Cancer Treatm Rep 1985; 12 (Suppl A): 67-71.
3. Lund B, Hansen M, Hansen OP, et al. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989; 7: 1469-73.
4. Lund B, Hansen M, Hansen OP, et al. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990; 8 (Suppl. 7): 1226-30.
5. Hillcoat B, Campbell JJ, Pepperell R, et al. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162-6.
6. Kuhnle H, Achterrath W, Friskkom R. Krankheit orientierte phase II Studie mit etoposide (nsc 141540) bei cisplatin refraktaeren ovarial karzinomen. Tumor Diagnostik Therapie 1984; 5: 152-5.
7. Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: DeVita VT, Hellmann S, Rosenberg SA eds. Cancer, Principles and Practice of Oncology, 4th edn. Philadelphia, PA: Lippincott, 1993: 409-17.
8. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organisation, 1979.
9. Armitage P. Statistical Methods in Medical Research. New York, NY: Blackwell, 1971.
10. Neijt JP. Treatment of advanced ovarian carcinoma: 10 years experience. Ann Oncol 1992; 3: 17-27.
11. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991; 303: 884-93.
12. Omura GA, Bundy BN, Berek JS, et al. Randomised trial of cyclofosfamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7 (Suppl. 4): 457-65.
13. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10 (Suppl. 5): 706-17.
14. Gruppo Interregionale Cooperative Oncologico Ginecologia: Randomised comparison of cisplatin with cyclofosfamide/cisplatin and with cyclofosfamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; ii: 353-9.